Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Johanna E.A. Portielje"'
Autor:
Heleen C. van der Hulst, Jessica M. van der Bol, Esther Bastiaannet, Johanna E.A. Portielje, Jan Willem T. Dekker
Publikováno v:
European Journal of Surgical Oncology. 49:724-729
Autor:
Nanon Labrie, Willem Jan W Bos, Anne M. Stiggelbout, Anouk M. Knops, Jessica de Graaf, Kim Brandes, Joyce E de Boer, Arwen H. Pieterse, Cornelia F Allaart, Johanna E.A. Portielje
Publikováno v:
Pieterse, A H, Brandes, K, de Graaf, J, de Boer, J E, Labrie, N H M, Knops, A, Allaart, C F, Portielje, J E A, Bos, W J W & Stiggelbout, A M 2022, ' Fostering Patient Choice Awareness and Presenting Treatment Options Neutrally : A Randomized Trial to Assess the Effect on Perceived Room for Involvement in Decision Making ', Medical Decision Making, vol. 42, no. 3, pp. 375-386 . https://doi.org/10.1177/0272989X211056334
Medical Decision Making, 42(3), 375-386. SAGE Publications Inc.
Medical Decision Making, 42(3), 375-386. SAGE PUBLICATIONS INC
Medical Decision Making, 42(3), 375-386. SAGE Publications Inc.
Medical Decision Making, 42(3), 375-386. SAGE PUBLICATIONS INC
Purpose Shared decision making calls for clinician communication strategies that aim to foster choice awareness and to present treatment options neutrally, such as by not showing a preference. Evidence for the effectiveness of these communication str
Autor:
Dirk J. A. Sonneveld, Frederiek van den Bos, Jan Willem T. Dekker, W.H. Steup, Ewout W. Steyerberg, Johanna E.A. Portielje, Marije M. Hamaker, Esteban T.D. Souwer, Esther Bastiaannet, Thijs A. Burghgraef
Publikováno v:
Cancers, Vol 13, Iss 3110, p 3110 (2021)
Cancers, 13(13). MDPI
Cancers
Volume 13
Issue 13
Cancers, 13(13). MDPI
Cancers
Volume 13
Issue 13
Introduction Older patients have an increased risk of morbidity and mortality after colorectal cancer (CRC) surgery. Existing CRC surgical prediction models have not incorporated geriatric predictors, limiting applicability for preoperative decision-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819f9bd8d4493eea7637e3e6ba7116cc
https://hdl.handle.net/1887/3276152
https://hdl.handle.net/1887/3276152
Autor:
A. Elise van Leeuwen-Stok, Harm van Tinteren, Els Platte, Erik van Werkhoven, Annelot van Rossum, I.A.M. Mandjes, HM Oosterkamp, Alwin D. R. Huitema, Robbert J. van Alphen, Sabine C. Linn, Daan van den Broek, Johanna E.A. Portielje, Marleen Kok, Petra M. Nederlof
Publikováno v:
Breast Care, 16(6), 598-606. KARGER
Breast Care (Basel)
Breast Care (Basel)
Background: The addition of bevacizumab to chemotherapy conferred a modest progression-free survival (PFS) benefit in metastatic triple-negative breast cancer (mTNBC). However, no overall survival (OS) benefit has been reported. Also, its combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a4391f76edcc1e91239cffbc442491c
https://www.karger.com/Article/Pdf/512200
https://www.karger.com/Article/Pdf/512200
Autor:
Johanna E.A. Portielje, Esther Bastiaannet, Frederiek van den Bos, Ewout W. Steyerberg, Esteban T.D. Souwer, Jan-Willem T. Dekker
Publikováno v:
Journal of Geriatric Oncology, 11(8), 1217-1228. ELSEVIER
Background: An increasing number of patients with Colorectal Cancer (CRC) is 65 years or older. We aimed to systematically review existing clinical prediction models for postoperative outcomes of CRC surgery, study their performance in older patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f45e9c198194f4b21bb50e61be91db
https://hdl.handle.net/1887/3184751
https://hdl.handle.net/1887/3184751
Autor:
W.H. Steup, Marta Fiocco, Johanna E.A. Portielje, Esther Bastiaannet, Shira I. Moos, Astrid Y. Bijlsma, Cornelis J. van Rooden, Jan Willem T. Dekker, Esteban T.D. Souwer, Frederiek van den Bos
Publikováno v:
European Journal of Surgical Oncology, 46(3), 462. W.B. Saunders Ltd
EJSO-European Journal of Surgical Oncology, 46(3), 462-469. ELSEVIER SCI LTD
EJSO-European Journal of Surgical Oncology, 46(3), 462-469. ELSEVIER SCI LTD
Background: Low lumbar skeletal muscle mass and density have been associated with adverse outcomes in different populations with colorectal cancer (CRC). We aimed to determine whether skeletal muscle mass, density, and physical performance are associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db7a149f389cb2078d3057192d803ebb
https://hdl.handle.net/1887/3181198
https://hdl.handle.net/1887/3181198
Autor:
Martijn P. Lolkema, Marco B. Polee, Olaf Loosveld, Paul Hamberg, Geert A. Cirkel, Stefan Sleijfer, Heinz-Josef Klümpen, Johanna E.A. Portielje, Emile E. Voest, Frank P. J. Peters, Vincent van der Noort, Gerard Groenewegen, Maartje Los, Maureen J.B. Aarts, Franchette W P J van den Berkmortel, Laurens V. Beerepoot, John B. A. G. Haanen, Metin Tascilar, M. Wouter Dercksen
Publikováno v:
JAMA oncology, 3(4), 501-508. American Medical Association
JAMA Oncology, 3(4), 501-508. American Medical Association
JAMA Oncology, 3(4), 501-508. American Medical Association
Importance To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. Objective To test our hypothesis that an 8-week rotati
Autor:
Alexander L T Imholz, Jesse J. Swen, Marlène H.W. van de Poel, Albert J. ten Tije, Paul Hamberg, Annemieke Cats, Femke M. de Man, Jos H. Beijnen, Miriam Koopman, Vincent O. Dezentjé, Emma Kienhuis, Caroline M.P.W. Mandigers, Peter Nieboer, Linda M. Henricks, Didier Meulendijks, André B.P. van Kuilenburg, Carin A.T.C. Lunenburg, Geert W.J. Frederix, Jan H.M. Schellens, Hilde Rosing, Henk-Jan Guchelaar, Helga J. Droogendijk, Rob L. H. Jansen, Frank J.F. Jeurissen, Ron H.J. Mathijssen, Hans Gelderblom, Arnold Baars, Geert Jan Creemers, Johanna E.A. Portielje, Erik van Werkhoven, Ron H.N. van Schaik
Publikováno v:
European Journal of Cancer, 107, 60. Elsevier Ltd
European Journal of Cancer, 107, 60. Elsevier Limited
European journal of cancer (Oxford, England, 107, 60-67. Elsevier Limited
European Journal of Cancer, 107, 60-67
European Journal of Cancer
European Journal of Cancer, 107, 60-67. Elsevier Ltd.
European Journal of Cancer, 107, 60-67. ELSEVIER SCI LTD
European Journal of Cancer, 107, 60. Elsevier Limited
European journal of cancer (Oxford, England, 107, 60-67. Elsevier Limited
European Journal of Cancer, 107, 60-67
European Journal of Cancer
European Journal of Cancer, 107, 60-67. Elsevier Ltd.
European Journal of Cancer, 107, 60-67. ELSEVIER SCI LTD
Background: Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often related to reduced activity of dihydropyrimidine dehydrogenase, the main metabol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1847de5cbd772fe5bd914816205b488
https://dspace.library.uu.nl/handle/1874/389408
https://dspace.library.uu.nl/handle/1874/389408
Autor:
Rob L. H. Jansen, Ron H.N. van Schaik, Henk-Jan Guchelaar, Johanna E.A. Portielje, Paul Hamberg, Didier Meulendijks, Jos H. Beijnen, Emma Kienhuis, Ron H.J. Mathijssen, Hans Gelderblom, Femke M. de Man, Frank J.F. Jeurissen, Geert W.J. Frederix, Arnold Baars, Jan H.M. Schellens, Helga J. Droogendijk, Marlène H.W. van de Poel, Hilde Rosing, Linda M. Henricks, Albert J. ten Tije, Annemieke Cats, Carin A.T.C. Lunenburg, Caroline M.P.W. Mandigers, Erik van Werkhoven, André B.P. van Kuilenburg, Peter Nieboer, Geert Jan Creemers, Miriam Koopman, Vincent O. Dezentjé, Alexander L T Imholz, Jesse J. Swen
Publikováno v:
The Lancet Oncology, 19(11), 1459-1467
The Lancet Oncology, 19(11), 1459. Lancet Publishing Group
LANCET ONCOLOGY, 19(11), 1459. Lancet Publishing Group
The Lancet Oncology
Lancet oncology, 19(11), 1459-1467. Elsevier Science
lancet oncology, 19(11), 1459-1467. Lancet Publishing Group
Lancet Oncology, 19(11), 1459-1467. Lancet Publishing Group
The Lancet Oncology, 19(11), 1459. Lancet Publishing Group
LANCET ONCOLOGY, 19(11), 1459. Lancet Publishing Group
The Lancet Oncology
Lancet oncology, 19(11), 1459-1467. Elsevier Science
lancet oncology, 19(11), 1459-1467. Lancet Publishing Group
Lancet Oncology, 19(11), 1459-1467. Lancet Publishing Group
Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD), mostly caused by genetic variants in the gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4283cc80c2ca08cc0f0a136e40a12b84
http://hdl.handle.net/1887/95617
http://hdl.handle.net/1887/95617
Autor:
Andrzej Piwowar, Fransje Aa Valster, Jeffrey P.B.M. Braak, Marije Ie Appels, Frits van Coevorden, Niels H Nielsen, Johanna E.A. Portielje, Jeroen Buijsen, Petra Flygare, Marije Slingerland, Nicole C.T. van Grieken, Jetske M. Meerum Terwogt, Maartje Los, Mattias Elmlund, Henk Boot, Rob L. H. Jansen, Johanna W. van Sandick, A. Haringhuizen, Johannes J. Bonenkamp, Harm van Tinteren, Edwin P.M. Jansen, Henk H. Hartgrink, Jaap De Boer, Anouk K. Trip, Ge Jpm Jonkers, Marie Louise Jespersen, Cecillia Lagerbäck, Per Edlund, Marco B Polée, Mats Perman, J (Hans)-Martin Mb Otten, Marjan A Van Dijk, Danny Houtsma, A (Bert) Jan Ten Tije, Arnold Baars, Olaf Jl Loosveld, Maud M. Geenen, Maarten C.C.M. Hulshof, Gerrit-Jan Veldhuis, Erik W Muller, Geert-Jan Creemers, Annelie Je Vulink, Quirijn A. J. Eijsbouts, Annerie Slot, Diane Grootenboers, Hein Putter, Ellen M Hendriksen, Maurice J.C. van der Sangen, Fabiënne A. R. M. Warmerdam, Tom Rozema, HA A. Maurits Swellengrebel, Henk K Van Halteren, Ate van der Gaast, Marcel Verheij, Richard Van Hilligersberg, Helene Hörberg, Pehr Lind, Annemieke Cats, Cornelis J.H. van de Velde, Jitty M Smit, Alex L. T. Imholz, Donald L. van der Peet, Aart Van Bochove, Henk M.W. Verheul, Adelheid Me Van der Torren-Conze, Frans L. G. Erdkamp, Dick Johan van Spronsen, Mark I. van Berge Henegouwen, Ernst Jan Spillenaar Bilgen, Johanna Mgh Van Riel, Marien O Den Boer, Hanneke W. M. van Laarhoven, Marjolein Em Rentinck, Ron C Rietbroek, Bengt Johansson, David Borg, Anders Johnsson, Aart Beeker, Reinoud J. B. Blaisse, Miriam Koopman, Daan Ten Bokkel Huinink, Karen J. Neelis, Elma Meershoek-Klein Kranenbarg, Djamila Boerma, Heleen M. Ceha, Bea C Tanis, Marie-Cecile Jc Legdeur, O Aart Van Dobbenburgh, Steven Vanhoutvin, Sjoerd Hovenga, Karolina Sikorska, Pètra M Braam, H Pieter van den Berg, Huub van der Mijle, Marianne Nordsmark, Bengt Glimelius
Publikováno v:
lancet oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21019f3b155741c37a17771cdb957cb
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html